A monoclonal antibody against the receptor for advanced glycation end products attenuates inflammatory and neuropathic pain in the mouse

European Journal of Pain (United Kingdom)

Volumn 20, Issue 4, 2016, Pages 607-614

  Brederson, J D ^a   Strakhova, M ^a   Mills, C ^a   Barlow, E ^a   Meyer, A ^a   Nimmrich, V ^a   Leddy, M ^a   Simler, G ^a   Schmidt, M ^a   Jarvis, M ^a   Lacy, S ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GABAPENTIN; MONOCLONAL ANTIBODY; FREUND ADJUVANT; IMMUNOLOGIC FACTOR;

ADULT; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; FEMALE; HEK293 CELL LINE; HUMAN; INFLAMMATORY PAIN; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; HYPERALGESIA; IMMUNOLOGY; METABOLISM; NEURALGIA; PATHOPHYSIOLOGY; SCIATIC NERVE; SPINAL CORD; SPINAL GANGLION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; GANGLIA, SPINAL; HUMANS; HYPERALGESIA; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED C57BL; NEURALGIA; NEURONS, AFFERENT; SCIATIC NERVE; SPINAL CORD;

EID: 84960480260     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/ejp.775     Document Type: Article

References (19)

1. Allette, Y.M., Due, M.R., Wilson, S.M., Feldman, P., Allette, Y., Khanna, R., White, F.A., (2014). Identification of a HMGB1 interaction with receptor for advanced glycation end products in a model of neuropathic pain. Brain Behav Immun 42, 169-177.
2. Bennett, G.J., Xie, Y.K., (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33, 87-107.
3. Bierhaus, A., Haslbeck, K.M., Humpert, P.M., Liliensiek, B., Dehmer, T., Morcos, M., Sayed, A.A., Andrassy, M., Schiekofer, S., Schneider, J., Schulz, J., Heuss, D., Neundörfer, B., Dierl, S., Huber, J., Tritschler, H., Schmidt, A.M., Schwaninger, M., Häring, H.U., Schleicher, E., Stern, D.M., Kasper, M., Arnold, B., Nawroth, P.P., (2004). Loss of pain perception in diabetic neuropathy is dependent on a receptor of the immune globulin superfamily. J Clin Invest 114, 1741-1751.
4. Bierhaus, A., Humpert, P.M., Morcos, M., Wendt, T., Chavkis, T., Arnold, B., Stern, D.M., Nawroth, P.P., (2005). Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83, 876-86.
5. Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53, 55-63.
6. Dixon, W.J., (1980). Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20, 441-462.
7. Feng, L., Matsumoto, C., Schwartz, A., Schmidt, A.M., Stern, D.M., Pile-Spellman, J., (2005). Chronic vascular inflammation in patients with type-2 diabetes. Diabetes Care 28, 379-84.
8. Haslbeck, K.M., Friess, U., Schleicher, E.D., Bierhaus, A., Nawroth, P.P., Kirchner, A., Pauli, E., Neundörfer, B., Heuss, D,. (2005). The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy. Acta Neuropathol. 110, 247-254.
9. Hein, G., Franke, S., (2002). Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41, 1163-1167.
10. Ibrahim, Z.A., Armour, C.L., Phipps, S., Sukkar, M.B., (2013). RAGE and TLRs: Relatives, friends or neighbours? Mol Immun 56, 739-744.
11. Lukic, I.K., Humpert, P.M., Nawroth, P.P., Bierhaus, A., (2008). The RAGE pathway: Activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci 1126, 76-80.
12. Misur, I., Zarkovic, K., Barada, A., Batelja, L., Milicevic, Z., Turk, Z., (2004). Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 41, 158-66.
13. Musumeci, D., Roviello, G.N., Montesarchio, D., (2014). An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 141, 347-357.
14. Ramasamy, R., Vannucci, S.J., Yan, S.S., Herold, K., Yan, S.F., Schmidt, A.M., (2005). Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16R-28R.
15. Ruster, M., Franks, S., Spath, M., Pongratz, D.E., Stein, G., Hein, G.E., (2005). Detection and elevated N-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 34, 460-63.
16. Shibasaki, M., Sasaki, M., Miura, M., Mizukoshi, K., Ueno, H., Hashimoto, S., Tanaka, Y., Amaya, F., (2010). Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 149, 514-21.
17. Sugimoto, K., Nishizawa, Y., Horiuchi, S., Yagihashi, S., (1997). Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40, 1380-7.
18. Sugimoto, K., Yasujima, M., Yagihashi, S., (2008). Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 14, 953-61.
19. Wendt, T.M., Tanji, N., Kislinger, T.R., Qu, W., Lu, Y., Bucciarelli, L.G., Rong, L., Bierhaus, A., Nawroth, P.P., Moser, B., Markowitz, G.S., Stein, G., Dágati, V., Stern, D.M., Schmidt, A.M., (2003). RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162, 1123-1137.